Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Synchrony Financial — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.37 (market cap $2.27B), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 10.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Synchrony Financial pays a 1.84% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | SYF | |
|---|---|---|
Market Cap | $2.27B | $23.99B |
Volume | 4,179,659 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $15.46 | $88.47 |
52-Week Low | $1.39 | $63.78 |
Enterprise Value | $2.14B | $24.23B |
Typical Hold Time | — | 28 Days |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synchrony Financial (SYF) trades at $71.93, down 0.32% today, with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 23.4% net income margin and 22.23% ROE, trading at attractive valuations (P/E 7.56x). Recent developments include partnerships with OpenAI and Vetspire to expand AI-driven commerce and veterinary financing capabilities, while Q3 2026 earnings are scheduled for October 20, 2026.
SYF presents a compelling value opportunity with strong earnings momentum and analyst consensus target of $87.58 (22% upside). However, technical weakness and increased investing outflows in 2026 create near-term headwinds. The stock offers shareholder returns through dividends and buybacks, but faces risks from consumer credit quality and competitive payment landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
